Optodrop-Co (Dorzolamide Hydrochloride, Timolol Maleate)

• Optodrop-Co combines dorzolamide and timolol to lower intraocular pressure in glaucoma and ocular hypertension.
• Open-angle glaucoma: reduces intraocular pressure to slow optic nerve damage.
• Ocular hypertension: lowers pressure to prevent progression to glaucoma.
• Secondary glaucoma: provides additional pressure control when monotherapy is insufficient.

• Dorzolamide inhibits carbonic anhydrase in the ciliary body, decreasing aqueous humor secretion, while timolol blocks β‑adrenergic receptors, reducing aqueous humor production. The combined effect results in a marked reduction of intraocular pressure, improving fluid outflow dynamics and protecting the optic nerve from pressure‑related injury. This dual mechanism provides a synergistic pressure‑lowering effect that is sustained with twice‑daily dosing and complements other ocular hypotensive agents when needed.

Optodrop-Co may cause ocular and systemic adverse reactions, most of which are mild and transient.

Common Side Effects

• Eye irritation or burning: transient discomfort after instillation.
• Blurred vision: temporary visual disturbance.
• Dry eye sensation: mild dryness.
• Taste alteration: bitter taste after drops.
• Conjunctival hyperemia: mild redness.
• Reduced tear production: occasional dryness.

Serious or Rare Side Effects

• Severe allergic reaction: swelling, rash, or difficulty breathing.
• Corneal edema: swelling of the cornea affecting vision.
• Systemic bradycardia: slowed heart rate, especially in patients with cardiac disease.
• Bronchospasm: airway constriction in asthmatic patients.
• Acute angle‑closure glaucoma: paradoxical pressure rise.
• Stevens‑Johnson syndrome: rare severe skin reaction.

Before prescribing Optodrop-Co, clinicians should evaluate patient history and monitor for specific risks.

• Cardiovascular assessment: check for bradycardia, heart block, or heart failure.
• Respiratory evaluation: avoid in patients with asthma or COPD due to bronchospasm risk.
• Pregnancy and lactation: use only if benefit outweighs potential risk; data limited.
• Concomitant beta‑blockers: monitor for additive systemic effects such as hypotension.
• Contact lens wear: advise removal before instillation as lenses may retain drug.
• Store at room temperature: keep in original container, protect from light and moisture.

Optodrop-Co can interact with systemic and ocular medications, altering efficacy or safety.

Major Interactions (Avoid)

• Systemic beta‑blockers: may cause excessive bradycardia or hypotension.
• Non‑selective beta‑blockers (e.g., propranolol): increase risk of bronchospasm.
• Other ocular carbonic anhydrase inhibitors (e.g., acetazolamide): may lead to over‑reduction of intraocular pressure.

Moderate Interactions (Monitor Closely)

• Topical sympathomimetics (e.g., phenylephrine): may diminish pressure‑lowering effect.
• Systemic carbonic anhydrase inhibitors (e.g., oral acetazolamide): additive IOP reduction.
• Anticholinergic eye drops: may affect pupil dynamics and drug absorption.